PLEGINE Drug Patent Profile
When do Plegine patents expire, and when can generic versions of Plegine launch?
Plegine is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in PLEGINE is phendimetrazine tartrate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Plegine
A generic version of PLEGINE was approved as phendimetrazine tartrate by CHARTWELL on October 30th, 1991.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PLEGINE?
- What are the global sales for PLEGINE?
- What is Average Wholesale Price for PLEGINE?
Summary for PLEGINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Patent Applications: | 547 |
| DailyMed Link: | PLEGINE at DailyMed |
US Patents and Regulatory Information for PLEGINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | PLEGINE | phendimetrazine tartrate | TABLET;ORAL | 012248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
